Journal of Clinical Oncology, Vol 15, 1333-1340, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin- containing therapy

SM Swain, FS Whaley, MC Gerber, MS Ewer, JR Bianchine and RA Gams
Comprehensive Breast Center, Washington, DC 20015-2034, USA. swainsm@aol.com

PURPOSE: To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC). PATIENTS AND METHODS: In two multicenter studies (088001 and 088006), patients were randomized to receive FAC and placebo (PLA) versus FAC and DZR. After a protocol amendment, all patients received open-label DZR after they had reached a cumulative doxorubicin dose of 300 mg/m2. Two groups were compared: 99 patients randomized to the PLA arms before the amendment who received FAC and PLA for at least seven courses (PLA group), and 102 patients randomized to the PLA arms after the amendment who received FAC and PLA for six courses followed by open-label DZR (PLA/DZR group). RESULTS: The hazards ratio of PLA to PLA/DZR was 3.5 (95% confidence interval [CI], 2.2 to 5.7; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at any cardiac event, ejection fraction changes, or congestive heart failure (CHF). The hazards ratio of PLA to PLA/DZR was 13.1 (95% CI, 3.7 to 46.0; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at the development of CHF. The overall incidence of CHF in the PLA/DZR group was 3%, compared with 22% in the PLA group (P < .001, Fisher's exact test). Twenty-six percent of PLA/DZR patients received at least 15 courses of therapy, compared with 5% of patients in the PLA group. These results do not appear to be attributable to a time trend. CONCLUSION: DZR is a highly effective cardioprotective agent when used in patients with advanced breast cancer who continue to receive doxorubicin-based chemotherapy after a cumulative doxorubicin dose of 300 mg/m2 has been reached.

This article has been cited by other articles:

				D. L. Hershman, R. B. McBride, A. Eisenberger, W. Y. Tsai, V. R. Grann, and J. S. Jacobson Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., July 1, 2008; 26(19): 3159 - 3165. [Abstract] [Full Text] [PDF]

				B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				E. V. Barry, S. E. Lipshultz, and S. E. Sallan Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention ASCO Educational Book, January 1, 2008; 2008(1): 448 - 453. [Abstract] [Full Text] [PDF]

				M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport, V. Stahalova, and On behalf of the Dexrazoxane Study Group Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy Ann. Onc., April 1, 2006; 17(4): 614 - 622. [Abstract] [Full Text] [PDF]

				J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry Cardiotoxicity of Cancer Therapy J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696. [Abstract] [Full Text] [PDF]

				X. Xu, H. L. Persson, and D. R. Richardson Molecular Pharmacology of the Interaction of Anthracyclines with Iron Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271. [Abstract] [Full Text] [PDF]

				K. F. Hofland, A. V. Thougaard, M. Sehested, and P. B. Jensen Dexrazoxane Protects against Myelosuppression from the DNA Cleavage-Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin Clin. Cancer Res., May 15, 2005; 11(10): 3915 - 3924. [Abstract] [Full Text] [PDF]

				S. Campos Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer Oncologist, August 1, 2003; 8(90002): 10 - 16. [Abstract] [Full Text] [PDF]

				S. H. Giordano, D. J. Booser, J. L. Murray, N. K. Ibrahim, Z. U. Rahman, V. Valero, R. L. Theriault, M. F. Rosales, E. Rivera, D. Frye, et al. A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3360 - 3368. [Abstract] [Full Text] [PDF]

				L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903. [Full Text] [PDF]

				G. N Hortobagyi Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79. [Abstract] [Full Text] [PDF]

				G. Williams, P. Cortazar, R. Pazdur, G. Batist, and L. Welles Developing Drugs to Decrease the Toxicity of Chemotherapy J. Clin. Oncol., July 15, 2001; 19(14): 3439 - 3441. [Full Text]

				M. L. Tetef, T. W. Synold, W. Chow, L. Leong, K. Margolin, R. Morgan, J. Raschko, S. Shibata, G. Somlo, Y. Yen, et al. Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies Clin. Cancer Res., June 1, 2001; 7(6): 1569 - 1576. [Abstract] [Full Text] [PDF]

				G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, et al. Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer J. Clin. Oncol., March 1, 2001; 19(5): 1444 - 1454. [Abstract] [Full Text] [PDF]

				J. A. Sparano, P. Hu, R. M. Rao, C. I. Falkson, A. C. Wolff, and W. C. Wood Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study J. Clin. Oncol., December 1, 1999; 17(12): 3828 - 3834. [Abstract] [Full Text] [PDF]

				K Hellmann Preventing the cardiotoxicity of anthracyclines by dexrazoxane BMJ, October 23, 1999; 319(7217): 1085 - 1086. [Full Text]

				M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]

				J. A. Sparano, J. Speyer, W. J. Gradishar, L. Liebes, R. Sridhara, S. Mendoza, D. Fry, and M. J. Egorin Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer J. Clin. Oncol., March 1, 1999; 17(3): 880 - 880. [Abstract] [Full Text] [PDF]

				B. B. Hasinoff and R. G. Aoyama Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and Its Two Active Ring-Opened Metabolites in the Rat Drug Metab. Dispos., February 1, 1999; 27(2): 265 - 268. [Abstract] [Full Text]